Skin Cancer Clinical Trial
Official title:
Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems
Objectives:
The objective of this study is to develop a valid and reliable measure of the symptom burden
experienced by patients with cancer experiencing disease-related skin problems and to
delineate this burden over time.
The Primary Aim is to develop and validate an M.D. Anderson Symptom Inventory (MDASI) module
(the MDASI-Derm), compliant with FDA standards for patient-reported outcomes (PROs), to
measure the severity of multiple symptoms and the impact of these symptoms on daily
functioning in patients with cancer-related skin problems. We hypothesize that the
MDASI-Derm will be valid and reliable for measuring the severity of multiple symptoms and
the impact of these symptoms on daily functioning in patients with cancer-related skin
problems.
The Secondary Aims are:
1. to develop a detailed description of the severity and interference with daily
activities of symptoms experienced by patients with cancer-related skin problems;
2. to assess the impact of symptom severity on standard function and quality of life (QOL)
measures including both quantitative (Eastern Cooperative Oncology Group [ECOG]
Performance Status, single-item QOL, and Skindex-16 scales) and qualitative measures
(patient interviews);
3. to evaluate the MDASI-Derm as an estimate of functional status and QOL in patients with
cancer-related skin problems;
4. to identify common clusters of symptoms and symptom patterns occurring over multiple
measurement time points in patients with cancer-related skin problems;
5. to define the qualitative symptom experience of patients with cancer-related skin
problems;
6. to explore the feasibility of the Interactive Voice Response (IVR) system in measuring
symptom severity and interference with daily activities over time in patients with
cancer-related skin problems.
Part I:
Interview:
If you agree to take part in this study, while you are at the clinic for a visit, you will
be interviewed about skin problems and other symptoms that you have had since you began
experiencing skin problems. The interview should take about 30 minutes to complete.
Part I:
Questionnaires:
After the interview, you will be asked to answer a general symptom questionnaire, a
quality-of-life questionnaire, a skin-specific questionnaire, and some demographic questions
(such as your age and marital status). It should take about 15 minutes to complete all 4
questionnaires.
Part II:
Symptom Questionnaires:
If you agree to take part in this study, you will complete a questionnaire about skin
problems and other symptoms you are having. This symptom questionnaire will ask you to rate
how severe your skin problems and other symptoms are and how the skin problems and other
symptoms affect the activities of your daily life. It should take about 5 minutes to
complete. You will complete the questionnaire at a routine clinic visit every 2 weeks for 1
year. If you do not have a clinic visit every 2 weeks, you will be called by an automated
phone system so you may complete the questionnaire at least 1 time every 2 weeks.
You can decide what time is most convenient for the automated phone system to call you. If
you are not available when the automated system calls, it will call you again at a later
time. You will be given a secure user name and identification number to use with the
automated phone system. The study staff will teach you how to use the automated phone
system.
Two (2) days after you begin the study, you will fill out the symptom questionnaire again.
You will take home a paper copy of the questionnaire with you from the clinic with a
pre-addressed, stamped envelope given to you by the research staff so you can return it. The
research staff will also ask for your telephone number so that they may contact you and
remind you to complete the questionnaire.
Quality-of-Life/Demographic Questionnaires:
At the first visit, you will also be asked some demographic questions (such as your age and
employment status). Answering these questions should take about 1 minute. Some of these
questions (such as employment status) will be repeated at regular clinic visits. You will
not be asked to do this more often than every 3-5 weeks.
At the first visit and at regular clinic visits, you will also rate your overall
quality-of-life. This should take about 1 minute to complete. You will not be asked to do
this more often than every 3-5 weeks.
At the first visit and at regular clinic visits, you will be asked to complete a second
questionnaire that asks specific questions about how problems with your skin affect the
quality of your life. This should take about 5 minutes to complete. You will not be asked to
do this more often than every 3-5 weeks.
Opinion Questionnaire:
If you are 1 of the first 20 participants enrolled in Part 2 of this study, you will be
asked questions about your opinion of the symptom questionnaire after you have completed it
for the first time. For example, you will be asked if the symptom questionnaire was easy to
understand and complete, and if there were any other questions that should be included. The
study staff will use your opinion to decide if changes should be made to the questionnaire
or if important symptom questions are missing from the questionnaire. This questionnaire
should take about 5 minutes to complete.
Part I:
Length of Study:
After you have completed the interview and questionnaires, your participation on this study
will be over.
Part II:
Length of Study You will be on study for 1 year. You will be off study after you complete
the last symptom questionnaire.
This is an investigational study. Up to 60 participants will take part in this study. Up to
20 will be enrolled in Part 1 of this study. Up to 40 participants will be enrolled in Part
2 of this study. All will be enrolled at MD Anderson.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT03740815 -
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
|
N/A | |
Recruiting |
NCT05779423 -
Cryoablation+Ipilimumab+Nivolumab in Melanoma
|
Phase 2 | |
Terminated |
NCT01468818 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT01820234 -
Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event
|
N/A | |
Completed |
NCT00535769 -
Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
|
Phase 0 | |
Completed |
NCT00526032 -
Melanoma Detection by Oblique-Incidence Optical Spectroscopy
|
N/A | |
Completed |
NCT00588341 -
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
|
Phase 2 | |
Active, not recruiting |
NCT01447199 -
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
|
||
Enrolling by invitation |
NCT04758988 -
AI Augmented Training for Skin Specialists
|
N/A | |
Not yet recruiting |
NCT04534868 -
Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area
|
N/A | |
Recruiting |
NCT04138342 -
Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer
|
Phase 1 | |
Completed |
NCT03673917 -
Cosmetology Students and Skin Cancer
|
N/A | |
Recruiting |
NCT04341064 -
Sun-safe Habits Intervention and Education
|
Phase 3 | |
Completed |
NCT04206995 -
Cancer Sensing: Evaluation of Odour Sampling Techniques
|
||
Recruiting |
NCT05574101 -
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05860881 -
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
|
Phase 3 | |
Completed |
NCT05146622 -
Virtual Sun Safe Workplaces Ph I
|
||
Recruiting |
NCT05068310 -
Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
|
||
Recruiting |
NCT03889899 -
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
|
N/A |